To clarify immune-mediated mechanisms in rheumatic heart disease caused by group A streptococcal infection, valve tissues from rheumatic patients with valvular heart disease who required valve replacement were studied for reactivity with monoclonal anti-CD4 or anti-CD8 monoclonal antibodies or anti-vascular cell adhesion molecule-1 (VCAM-1). At the valve surface, CD4 + and CD8 + T lymphocytes were adherent to valve endothelium and penetrated through the subendothelial layer. T cell extravasation into the valve through the surface valvular endothelium appeared to be an important event in the development of rheumatic heart disease. VCAM-1 was expressed on the valvular endothelium in rheumatic valves. Evidence suggested that the pathogenesis of rheumatic heart disease involved the activation of surface valvular endothelium with the expression of VCAM-1 and the extravasation of CD4 + and CD8 + lymphocytes through the activated endothelium into the valve. Lymphocytic infiltration through the valve surface endothelium has not been appreciated as a potential initiating step in disease pathogenesis.
To clarify immune-mediated mechanisms in rheumatic heart disease caused by group A streptococcal infection, valve tissues from rheumatic patients with valvular heart disease who required valve replacement were studied for reactivity with monoclonal anti-CD4 or anti-CD8 monoclonal antibodies or anti-vascular cell adhesion molecule-1 (VCAM-1). At the valve surface, CD4 + and CD8 + T lymphocytes were adherent to valve endothelium and penetrated through the subendothelial layer. T cell extravasation into the valve through the surface valvular endothelium appeared to be an important event in the development of rheumatic heart disease. VCAM-1 was expressed on the valvular endothelium in rheumatic valves. Evidence suggested that the pathogenesis of rheumatic heart disease involved the activation of surface valvular endothelium with the expression of VCAM-1 and the extravasation of CD4 + and CD8 + lymphocytes through the activated endothelium into the valve. Lymphocytic infiltration through the valve surface endothelium has not been appreciated as a potential initiating step in disease pathogenesis.
Group A streptococci are important human pathogens that cause a number of suppurative infections in humans, including pharyngitis, which can lead to acute rheumatic fever (ARF) in a susceptible host [1] . ARF is a leading cause of heart disease in children worldwide [1] , and since 1985 there has been a resurgence of ARF in the United States [2] . The pathogenesis of ARF is complex and may depend on a number of streptococcal and host factors, particularly autoimmune responses against host tissues. Both hereditary and environmental factors influence susceptibility to ARF [1] .
Major clinical manifestations of ARF include carditis/valvulitis, chorea, polyarthritis, erythema marginatum, and sub- Human experimentation guidelines of the US Department of Health and Human Services and those of the authors' institutions were followed in the conduct of the clinical research. cutaneous nodules [3] . Carditis is the most serious [4] . Pathologic signs of rheumatic carditis, which include Anitshkow myocytes [5] and Aschoff's nodules, may develop in heart tissues of ARF patients [4] . In valvular injury, verrucae or nodules form on the mitral valve with edema and cellular infiltration of the leaflets. Valves are damaged, resulting in valvular stenosis or regurgitation. Previous studies showed the presence of both CD4 ϩ and CD8 ϩ T cell subsets within ARF valves [6] [7] [8] and major histocompatibility complex (MHC) class II antigen expression on vessel endothelium and valvular fibroblasts [7, 9] .
Serum samples from patients with ARF contain heartreactive or myosin-reactive antibodies, frequently in high titers, which are also found in the myocardium and valve tissues of ARF patients [1] . In studies of antistreptococcal/antiheart monoclonal antibodies (MAbs) from rheumatic carditis, the cross-reactive antibodies react with both myocardium and valvular endothelium [10] . Binding of antistreptococcal/antimyosin antibodies to valvular endothelium may serve as an inflammatory signal to up-regulate the expression of adhesion molecules on valvular surface endothelium, which then may serve as an infiltration site for lymphocytes into the valve. In this study, we investigated mitral valves from persons with ARF, to determine whether valve surface endothelium (endocardium) might play a role in the pathogenesis of ARF.
Methods

Rheumatic carditis patients.
Six patients with a clinical diagnosis of rheumatic valvulitis were assessed, but only 2 patients had enough intact valvular endothelium for study inclusion. All presented with mitral regurgitation.
Tissues. Valve specimens were obtained during surgery or autopsy from patients with rheumatic heart disease at the University of Witwatersrand (Johannesburg, South Africa) and at the King Faisal Hospital (Riyadh, Saudi Arabia). The patients were 8-65 years old. Rheumatic valves were compared with 3 anatomically and functionally normal mitral valves from autopsy of middle-aged men after myocardial infarction or heart failure. Only 2 rheumatic valves, from children 8-11 years old, contained enough surface endothelium to yield information for our study. Normal tonsils and lymph nodes were used as positive controls for immunostaining of T lymphocyte subsets, and tonsillar tissue was used as a positive control for activated endothelial cells. Tissues were fixed in 10% neutral buffered formalin and were embedded in paraffin.
Histology. Examination of hematoxylin-eosin (HE)-stained sections were characterized according to the cellular infiltration, fibrosis (scarring), neovascularization, and mineralization in the valves. Valves had lymphocytic infiltrates with evidence of chronic valvulitis, defined by the presence of inflammatory cellular infiltrates (predominantly lymphocytes), with scarring, neovascularization, and absence of significant mineralization. Mineralization was not observed in patients !13 years old.
MAbs. All MAbs used are IgG1. Anti-CD4 MAb (clone DD4-2; Southern Biotech Associates) reacts with the 55-60-kDa protein found on 54% of peripheral blood lymphocytes and 50% of thymocytes, and anti-CD8 MAb (clone C8/144B; Southern Biotech) reacts with the 13 C-terminal amino acids of the cytoplasmic domain of the CD8 molecule. Anti-vascular cell adhesion molecule-1 (VCAM-1; CD 106) MAb (clone 1.4C3; Dako) reacts with the human VCAM-1 domain 2. The isotype control MAb (no. 102-01, lot A085-UA25) was obtained from Southern Biotech.
Anti-CD4 MAb specificity was confirmed by reaction with formalin-fixed CD4 ϩ CD8 Ϫ cells (ATCC clone CRL 2105). Anti-CD8 MAb specificity was tested by using formalin-fixed human peripheral blood lymphocytes isolated by ficoll-hypaque gradient. The percentage of cells stained (∼28%) was consistent with the expected peripheral blood population of CD8 ϩ lymphocytes. Histochemistry and immunohistochemistry. We placed 4-5-mmthick tissue sections on slides (ProbeOn Plus; Fisher Biotech) and processed them for HE staining, as described elsewhere [11] . Valve tissue sections were graded according to degree of fibrosis or scarring, inflammatory cellular infiltrates, neovascularization, and mineralization on a scale of 0 to у4.
Tissue sections were processed for immunochemistry with Microprobe System reagents (Research Genetics) at room temperature, unless otherwise specified. Sections were deparaffinized in a 3:1 mixture of Hemo-D:xylene, were rinsed in 100% ethanol, were washed in auto wash (50 mM Tris [pH 7.5] and 0.1% Triton-X 100), were incubated in Protein Blocker for 15 min at 37ЊC, and were washed again in auto wash. Sections then were incubated with one of the following MAbs: anti-CD4 (100 mg/mL), anti-CD8 (10 mg/mL), anti-VCAM-1 (10 mg/mL), or the isotype control IgG1 (100 mg/mL) for 2 h, and then were washed in auto wash and were incubated for 20 min at 37ЊC with universal secondary biotinylated antibody diluted 2:1 with PBS. Sections were washed with auto wash, were incubated with streptavidin alkaline phosphatase (Dako) at 1.5 mg/mL (in 100 mM Tris, 500 mM NaCl, 5 mM MgCl 2 , and 0.1% Tween 20 [pH 8.0]) for 15 min at 37ЊC, were washed with auto wash, and were treated with fast red substrate (BioGenex) for 15 min at 37ЊC. Sections then washed again in auto wash, were counterstained with HE, and were mounted (Crystal Mount; Biomeda). Before immunostaining with anti-CD8 and anti-VCAM-1 MAbs, deparaffinized sections were subjected to antigen retrieval by microwave treatment for 15 min in citrate buffer (pH 6), as described elsewhere [12] .
Results
Immunohistochemistry of rheumatic valves: lymphocyte subsets.
We used anti-CD4 and anti-CD8 MAbs to distinguish helper/inducer from cytotoxic/suppressor T lymphocytes, respectively. CD4 ϩ T lymphocytes were localized both along the superficial endothelial (endocardium) lining of the valve and immediately beneath the valvular endothelium (figure 1). Both mitral valve specimens contained infiltrates of CD4 ϩ lymphocytes, including adherence to the surface endothelium and migration of the CD4 ϩ lymphocytes through the endothelial layer of the rheumatic valve ( figure 1A and 1B) . CD8 ϩ lymphocytes also adhered to the valvular endothelium and infiltrated the valvular lesion ( figure 1C) . The isotype control MAb did not react with the rheumatic valve ( figure 1D ). Thus, there was evidence of T lymphocyte adherence to valve endothelium with extravasation through the endothelium. Neovascularization of diseased valves was also accompanied by the extravasation of CD4 ϩ and CD8 ϩ lymphocytes through the newly formed vessel walls into surrounding scar tissue (data not shown).
Valvular endothelium. To investigate the role of the surface endothelium in the extravasation of T lymphocytes into the valve directly from the blood, anti-VCAM-1 antibody was reacted with the valve sections. Rheumatic valvular endothelium expressed VCAM-1 on the valve surface endothelium (figure 2A). Rheumatic valve tissue sections did not react with the isotype MAb control ( figure 2B ). Anti-VCAM-1 did not react with the endothelium of 3 normal heart valve controls (not shown).
Discussion
In our study of rheumatic valves, the valve surface endothelium was a prominent site of lymphocytic infiltration in rheumatic heart disease, and lymphocytes adhered to superficial valve surface endothelium that expressed VCAM-1. Endothelial transmigration of lymphocytes at the valve surface endothelium may be an important initial step in disease pathogenesis.
Previous studies showed CD4 ϩ and CD8 ϩ lymphocytic infiltrates in neovascularized regions of the valve [7] . Rheumatic valves with intact endothelium were observed [5] , but the significance of the valve surface endothelium (endocardium) in the disease pathogenesis was not recognized. Previous work focused on the identity of Anitshkow cells and Aschoff's lesions [6, 13] . The pathology of Aschoff's body was elegantly described by Stollerman [4] . Our work focused on the importance of the valve surface endothelium in the pathogenesis of rheumatic carditis.
Lesions within ARF valves contain both CD4 ϩ and CD8 ϩ lymphocytes, and MHC antigens are expressed on macrophagelike cells in the lesions [7, 9] . A macrophage cell type has also been described in ARF lesions [13] . The presence of activated macrophages in rheumatic lesions is consistent with granuloma formation and the development of a CD4 ϩ Th1 lymphocyte response. Cytokine profile studies suggest the production of tumor necrosis factor-a and interleukin-1 by macrophages in Aschoff's bodies [14] . Hypothetically, the production of interferon-g as a product of a Th1 granulomatous response would enhance the cytotoxic activity of the CD8 ϩ lymphocytes present in the lesions, but in fewer numbers than the CD4 ϩ lymphocytes (not shown). We found evidence of immune mechanisms in the pathogenesis of rheumatic carditis. Initial streptococcal infection with the activation of B and T lymphocytes by streptococcal antigens and superantigens in susceptible patients would lead to antibody and cytokine production [1] . The reaction of antistreptococcal/antimyosin antibodies from rheumatic carditis with the valve endocardium supports the hypothesis that cross-reactive antibodies may bind to the endothelium and lead to inflammation, cellular infiltration, and valve scarring [10] . The binding of cross-reactive antibodies to valvular endothelial cells in ARF may up-regulate VCAM-1 on the endothelium. Influential cytokines may also affect the endothelium and the expression of VCAM-1. In either case, the valve would become a localized microenvironment for continual cytokine production and lymphocyte infiltration.
Expression of VCAM-1 on the endothelium is a hallmark of inflammation and heralds cellular infiltration [15] . Although it may not be surprising to find VCAM-1 expressed on rheumatic valvular surface endothelium, it has not been recognized previously. VCAM-1 interacts with very late antigen-4 on activated lymphocytes and leads to the extravasation of activated CD4 ϩ and CD8 ϩ lymphocytes into the valve tissue. Scarring is an important event in the progression of valvular disease, because it is accompanied by neovascularization of the otherwise avascular tissue of the valve. The fact that the valve is avascular underscores the importance of our findings that extravasation would initially occur through the endocardium. Since the valve is normally avascular, transendothelial migration of lymphocytes through the endothelial surface would play an important role in the pathogenesis of valvular heart disease. Once the leaflets become inflamed through the valvular surface endothelium and neovascularization occurs, lymphocytes can infiltrate the valve both through the valvular surface endothelium from without and through the neovascularization from within. Even in mineralized valve lesions of older persons, a lymphocytic infiltrate was present, indicating progress of persistent disease in the valve. The role of activated endothelium would obviously play a dramatic role in the initial development of rheumatic valvulitis and the progression of the disease throughout a lifetime.
In summary, our findings support the hypothesis that activated valve surface endothelium binds activated T cells, which extravasate into the valve and lead to the cycle of scarring, neovascularization, and infiltration of lymphocytes. The avascular valvular tissue is normally protected by the endothelium until some initiating factor, which could be antibody, influential cytokines, or both, breaks the endothelial barrier to the valve and allows for the cycle of cellular infiltration and scarring to begin. The data suggest that the mechanism of pathogenesis in rheumatic carditis begins at the valve surface endothelium.
